| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Results showed reductions in heart attack, stroke and heart failure events in all patients with even greater benefit for heart failure events among patients with longer diabetes duration
New analysis further differentiates INPEFA among SGLT inhibitors
THE WOODLANDS, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that a post-hoc analysis of Phase 3 data from the SCORED clinical trial demonstrated that INPEFA® (sotagliflozin) reduced the risk of major adverse cardiovascular events (MACE) and heart failure (HF) events across the spectrum of diabetes duration. Researchers noted that HF patients with longer durations of diabetes derived greater benefit from INPEFA, even controlling for similar baseline HbA1c, yet all patients regardless of diabetes duration benefited from the therapy. These findings were presented August 30th at the European Society of Cardiology (ESC) Congress 2024 in London, United Kingdom and online.
Diabetes duration is a well-established significant risk factor for cardiovascular (CV) disease and its progression. People with longer diabetes duration have a higher CV disease risk. The objective of this analysis of SCORED, one of two pivotal studies that led to FDA approval of INPEFA for heart failure in May 2023, was to evaluate if diabetes duration modifies the efficacy of INPEFA. The primary endpoint was a composite of CV death, HF hospitalization, and urgent heart failure visit events. Secondary endpoints included MACE: CV death, nonfatal heart attack and nonfatal stroke.
Posted In: LXRX
